ZyVersa Short Long Term Debt Total from 2010 to 2024
| ZVSA Stock | 1.07 0.04 3.60% |
Short and Long Term Debt Total | First Reported 2010-12-31 | Previous Quarter 8.7 K | Current Value 8.2 K | Quarterly Volatility 2.2 M |
Check ZyVersa Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ZyVersa Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 K, Interest Expense of 444.5 K or Selling General Administrative of 11.8 B, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0832. ZyVersa financial statements analysis is a perfect complement when working with ZyVersa Therapeutics Valuation or Volatility modules.
ZyVersa | Short Long Term Debt Total |
Latest ZyVersa Therapeutics' Short Long Term Debt Total Growth Pattern
Below is the plot of the Short Long Term Debt Total of ZyVersa Therapeutics over the last few years. It is ZyVersa Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ZyVersa Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Short Long Term Debt Total | 10 Years Trend |
|
Short Long Term Debt Total |
| Timeline |
ZyVersa Short Long Term Debt Total Regression Statistics
| Arithmetic Mean | 3,417,724 | |
| Geometric Mean | 1,412,417 | |
| Coefficient Of Variation | 64.88 | |
| Mean Deviation | 1,350,338 | |
| Median | 3,817,156 | |
| Standard Deviation | 2,217,254 | |
| Sample Variance | 4.9T | |
| Range | 9.1M | |
| R-Value | (0.34) | |
| Mean Square Error | 4.7T | |
| R-Squared | 0.11 | |
| Significance | 0.22 | |
| Slope | (166,850) | |
| Total Sum of Squares | 68.8T |
ZyVersa Short Long Term Debt Total History
About ZyVersa Therapeutics Financial Statements
ZyVersa Therapeutics stakeholders use historical fundamental indicators, such as ZyVersa Therapeutics' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although ZyVersa Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ZyVersa Therapeutics' assets and liabilities are reflected in the revenues and expenses on ZyVersa Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ZyVersa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 8.7 K | 8.2 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out the analysis of ZyVersa Therapeutics Correlation against competitors. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.